221 studies found for:    Open Studies | "Triplets"
Show Display Options
Rank Status Study
21 Recruiting Carboplatin and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Locally Advanced or Inflammatory Triple Negative Breast Cancer
Conditions: Inflammatory Breast Cancer;   Stage II Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer;   Triple-negative Breast Cancer
Interventions: Drug: carboplatin;   Drug: paclitaxel albumin-stabilized nanoparticle formulation;   Other: laboratory biomarker analysis
22 Recruiting Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer
Conditions: Estrogen Receptor Negative;   HER2/Neu Negative;   Ovarian Endometrioid Adenocarcinoma;   Ovarian Serous Cystadenocarcinoma;   Ovarian Serous Surface Papillary Adenocarcinoma;   Progesterone Receptor Negative;   Recurrent Breast Carcinoma;   Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma;   Triple-Negative Breast Carcinoma
Interventions: Drug: Olaparib;   Drug: Cediranib Maleate;   Other: Laboratory Biomarker Analysis
23 Not yet recruiting PARP Inhibitor BMN-673 in Treating Patients With BRCA1 and BRCA2 Wild-Type, Metastatic or Recurrent, Triple-Negative or HER2-Negative Breast Cancer
Conditions: Estrogen Receptor Negative;   HER2/Neu Negative;   Male Breast Carcinoma;   Progesterone Receptor Negative;   Metastatic Breast Carcinoma;   Stage IV Breast Cancer;   Triple-Negative Breast Cancer
Interventions: Drug: PARP Inhibitor BMN-673;   Other: Laboratory Biomarker Analysis
24 Recruiting Randomized Controlled Trial of Genomically Directed Therapy in Patients With Triple Negative Breast Cancer
Conditions: Triple Negative (ER-/PR-/HER2-) Invasive Breast Cancer;   Breast Cancer
Interventions: Drug: Genomically Directed Monotherapy;   Other: Observation/Standard Therapy
25 Recruiting BRCA1-associated DNA Repair Dysfunction in Patients With Early Triple Negative Breast Cancer Treated With Neoadjuvant Platinum-based Chemotherapy
Condition: Early Triple Negative Breast Cancer
Intervention: Drug: Doxorubicin, Paclitaxel, Cisplatin
26 Unknown  Maraviroc (Celsentri) With Raltegravir and Darunavir/Ritonavir for the Treatment of Triple Class Failure in Adult HIV-1 Infected Patients
Conditions: HIV-1 Adults Patients;   AIDS;   Triple Class Failure
Interventions: Drug: maraviroc;   Drug: Raltegravir;   Drug: Darunavir/ritonavir
27 Recruiting Capecitabine + BKM120 TNBC BC Brain Met
Conditions: Triple Negative Breast Cancer;   Brain Metastases;   Breast Cancer
Interventions: Drug: BKM120;   Drug: capecitabine
28 Recruiting AZD8186 First Time In Patient Ascending Dose Study
Conditions: Advanced Castrate-resistant Prostate Cancer (CRPC);;   Squamous Non-Small Cell Lung Cancer (sqNSCLC);;   Triple Negative Breast Cancer (TNBC)
Intervention: Drug: AZD8186
29 Not yet recruiting Pegylated Liposomal Doxorubicin Hydrochloride and Carboplatin Followed by Surgery and Paclitaxel in Treating Patients With Triple Negative Stage II-III Breast Cancer
Conditions: Estrogen Receptor-negative Breast Cancer;   HER2-negative Breast Cancer;   Progesterone Receptor-negative Breast Cancer;   Stage IIA Breast Cancer;   Stage IIB Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer;   Triple-negative Breast Cancer
Interventions: Drug: pegylated liposomal doxorubicin hydrochloride;   Drug: epirubicin hydrochloride;   Drug: carboplatin;   Procedure: therapeutic conventional surgery;   Drug: paclitaxel;   Other: laboratory biomarker analysis;   Other: quality-of-life assessment
30 Recruiting Eribulin Mesylate and Everolimus in Treating Patients With Triple-Negative Metastatic Breast Cancer
Conditions: Estrogen Receptor Negative;   HER2/Neu Negative;   Progesterone Receptor-negative;   Recurrent Breast Carcinoma;   Stage IV Breast Cancer;   Triple-negative Breast Carcinoma;   Breast Adenocarcinoma
Interventions: Drug: everolimus;   Drug: eribulin mesylate;   Other: pharmacological study;   Other: laboratory biomarker analysis
31 Recruiting Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Bevacizumab Followed By Bevacizumab and Erlotinib Hydrochloride in Treating Patients With Metastatic Breast Cancer
Conditions: Estrogen Receptor-negative Breast Cancer;   HER2-negative Breast Cancer;   Progesterone Receptor-negative Breast Cancer;   Recurrent Breast Cancer;   Stage IV Breast Cancer;   Triple-negative Breast Cancer
Interventions: Drug: paclitaxel albumin-stabilized nanoparticle formulation;   Biological: bevacizumab;   Drug: erlotinib hydrochloride;   Other: laboratory biomarker analysis
32 Not yet recruiting Neoadjuvant Carboplatin and Docetaxel in TNBC
Condition: Triple-negative Breast Cancer
Interventions: Drug: Paclitaxel;   Drug: Carboplatin;   Drug: Doxorubicin;   Drug: Cyclophosphamide;   Drug: Docetaxel
33 Recruiting A Study Evaluating PF-03084014 In Patients With Advanced Breast Cancer With Or Without Notch Alterations
Condition: Triple Negative Breast Neoplasms
Intervention: Drug: PF-03084014
34 Not yet recruiting Romidepsin Plus Cisplatin in Locally Recurrent or Metastatic TNBC
Condition: Triple-Negative Breast Cancer
Interventions: Drug: Romidepsin;   Drug: Cisplatin
35 Recruiting Study of BMN-673 With Carboplatin and Paclitaxel in Patients With Advanced BRCA-mutated Solid Tumor or Triple Negative Metastatic Breast Cancer
Conditions: Triple Negative Metastatic Breast Cancer;   BRCA-mutated Solid Tumor
Interventions: Drug: BMN-673;   Drug: Carboplatin;   Drug: Paclitaxel
36 Not yet recruiting RNA-Immunotherapy of IVAC_W_bre1_uID and IVAC_M_uID
Condition: Triple Negative Breast Cancer (TNBC)
Interventions: Biological: IVAC_W_bre1_uID;   Biological: IVAC_W_bre1_uID/IVAC_M_uID
37 Recruiting Pilot Study to Determine Biodistribution of MM-398 and Feasibility of Ferumoxytol as a Tumor Imaging Agent
Conditions: Solid Tumors;   Triple Negative Breast Cancer;   Non Small Cell Lung Cancer;   Colorectal Cancer;   ER/PR Positive Breast Cancer;   Pancreatic Cancer;   Ovarian Cancer;   Gastric Cancer;   Gastro-Esophageal Junction Adenocarcinoma;   Head and Neck Cancer
Intervention: Drug: Ferumoxytol followed by MM-398
38 Recruiting Safety Study of MGA271 in Refractory Cancer
Conditions: Prostate Cancer;   Melanoma;   Renal Cell Carcinoma;   Triple-negative Breast Cancer;   Head and Neck Cancer;   Bladder Cancer;   Non-small Cell Lung Cancer
Intervention: Biological: MGA271
39 Recruiting An Open-Label, Multicenter, Phase 1/2 Study of Poly(ADP-Ribose) Polymerase (PARP) Inhibitor E7449 as Single Agent in Subjects With Advanced Solid Tumors or With B-cell Malignancies and in Combination With Temozolomide (TMZ) or With Carboplatin and Paclitaxel in Subjects With Advanced Solid Tumors
Conditions: Malignant Solid Tumour;   Ovarian Cancer;   Triple Negative Breast Cancer;   Advanced Melanoma;   B-cell Malignancy, Low-grade
Interventions: Drug: E7449 alone;   Drug: E7449 plus TMZ;   Drug: E7449 plus carboplatin and paclitaxel
40 Recruiting cMet CAR RNA T Cells Targeting Breast Cancer
Conditions: Metastatic Breast Cancer;   Triple Negative Breast Cancer
Intervention: Biological: cMet RNA CAR T cells

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years